Merck to pay $5bn in rofecoxib claimsBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39398.517176.DB (Published 15 November 2007) Cite this as: BMJ 2007;335:1011
- Fred Charatan
The US drug company Merck announced last week that it will pay $4.85bn (£2.3bn; €3.3bn) to settle 26 600 lawsuits, representing 47 000 plaintiffs, in addition to 265 possible class action cases, arising out of the use of rofecoxib (Vioxx).
The agreement is to cover cases filed in federal and state courts, and depends on 85% of all plaintiffs dropping their cases. The money will be paid into a settlement fund for claims that qualify. In a …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial